DURHAM – A life science startup focusing on the use of nanotechnology in delivery of drugs is raising a $2 million of investment capital.
According to an SEC filing on Wednesday NuRevelation has raised $250,000 in equity.
The NCBiotech Center describes the company as a developer of “drug delivery methods for pharmaceuticals, nutraceuticals and cannabinoids.”
Says the company at its website: “NuRevelation is pioneering the use of All-natural self-assembling nanoparticles to encapsulate a variety of nutraceuticals, cannabinoids and pharmaceuticals.”
Launched in 2019, NuRevelation is seeking patents for its technology.
CEO Allen Wilson signed the filing.
The following graphic from NuRevelation outlines the company’s approach and technology:
NuRevelation graphic
